Use of fucoidan to treat renal diseases: A review of 15 years of clinic studies

doi:10.1016/bs.pmbts.2019.03.011

CORC > 海洋研究所 > 中国科学院海洋研究所 > 实验海洋生物学重点实验室

	Use of fucoidan to treat renal diseases: A review of 15 years of clinic studies
	Wang, Jing1,2,3 ; Geng, Lihua 1,2,3; Yue, Yang1,2,3 ; Zhang, Quanbin 1,2,3
刊名	GLYCANS AND GLYCOSAMINOGLYCANS AS CLINICAL BIOMARKERS AND THERAPEUTICS, PT B
	2019
卷号	163 页码:95-111
ISSN号	1877-1173
DOI	10.1016/bs.pmbts.2019.03.011
通讯作者	Wang, Jing(jingwang@qdio.ac.cn) ; Zhang, Quanbin(qbzhang@qdio.ac.cn)
英文摘要	Fucoidan is a sulfated polysaccharide extracted from brown seaweeds. Studies have shown that fucoidan has curative effects on the chronic renal failure, acute kidney injury, and diabetic nephropathy both in vitro and in vivo. Saccharina japonica is the most economically important brown seaweed cultivated in China and is consumed as a marine vegetable in East Asia. Over the past thousand years, Chinese people have traditionally used this plant to cure edema, a symptom of kidney diseases. The fucoidan extracted from Saccharina japonica is composed primarily of fucose and galactose with smaller amounts of other monosaccharides. Structure-activity relationship studies reveal that the molecular weight, monosaccharide compositions, the sulfation degree and the positions of sulfates influences the renoprotective activity. Low molecular weight fucoidan exhibits better activity than fucoidan. Pharmacological studies indicate that fucoidan inhibits renal fibrosis and glomerular sclerosis by reducing the accumulation of extracellular matrix. In addition, fucoidan reduces the inflammatory response and P-selectin expression, maintains the glomerular basement membrane and glomerular structural integrity, improves glomerular filtration function, and protects renal glycosaminoglycans from abnormal degradation. The effective constituent of Haikun Shenxi capsule (HSC) is the fucoidan extracted from Saccharina japonica. HSC was approved for treating renal diseases by the Chinese Food and Drug Administration in 2003. Based on the results of peer-reviewed publications, we will recapitulate the structure, pharmacology, reported clinical cases, clinical efficacy, and future perspectives of HSC. This review will summarize the knowledge of HSC gained in China to stimulate in-depth academic and clinical studies of HSC world widely.
WOS研究方向	Biochemistry & Molecular Biology
语种	英语
出版者	ELSEVIER ACADEMIC PRESS INC
WOS记录号	WOS:000486145100007
内容类型	期刊论文
源URL	[http://ir.qdio.ac.cn/handle/337002/162810]
专题	海洋研究所_实验海洋生物学重点实验室
通讯作者	Wang, Jing; Zhang, Quanbin
作者单位	1.Chinese Acad Sci, Ctr Ocean Mega Sci, Qingdao, Shandong, Peoples R China 2.Qingdao Natl Lab Marine Sci & Technol, Lab Marine Biol & Biotechnol, Qingdao, Shandong, Peoples R China 3.Chinese Acad Sci, Inst Oceanol, Key Lab Expt Marine Biol, Qingdao, Shandong, Peoples R China
推荐引用方式 GB/T 7714	Wang, Jing,Geng, Lihua,Yue, Yang,et al. Use of fucoidan to treat renal diseases: A review of 15 years of clinic studies[J]. GLYCANS AND GLYCOSAMINOGLYCANS AS CLINICAL BIOMARKERS AND THERAPEUTICS, PT B,2019,163:95-111.
APA	Wang, Jing,Geng, Lihua,Yue, Yang,&Zhang, Quanbin.(2019).Use of fucoidan to treat renal diseases: A review of 15 years of clinic studies.GLYCANS AND GLYCOSAMINOGLYCANS AS CLINICAL BIOMARKERS AND THERAPEUTICS, PT B,163,95-111.
MLA	Wang, Jing,et al."Use of fucoidan to treat renal diseases: A review of 15 years of clinic studies".GLYCANS AND GLYCOSAMINOGLYCANS AS CLINICAL BIOMARKERS AND THERAPEUTICS, PT B 163(2019):95-111.